To better understand the role of irisin in humans, we examined the effects of irisin in human primary adipocytes and fresh human subcutaneous white adipose tissue (scWAT). Human primary adipocytes derived from 28 female donors' fresh scWAT were used to examine the effects of irisin on browning and mitochondrial respiration, and preadipocytes were used to examine the effects of irisin on adipogenesis and osteogenesis. Cultured fragments of scWAT and perirenal brown fat were used for investigating signal transduction pathways that mediate irisin's browning effect by Western blotting to detect phosphorylated forms of p38, ERK, and STAT3 as well as uncoupling protein 1 (UCP1). Individual responses to irisin in scWAT were correlated with basal expression levels of brown/beige genes. Irisin upregulated the expression of browning-associated genes and UCP1 protein in both cultured primary mature adipocytes and fresh adipose tissues. It also significantly increased thermogenesis at 5 nmol/l by elevating cellular energy metabolism (OCR and ECAR). Treating human scWAT with irisin increased UCP1 expression by activating the ERK and p38 MAPK signaling. Blocking either pathway with specific inhibitors abolished irisin-induced UCP1 upregulation. However, our results showed that UCP1 in human perirenal adipose tissue was insensitive to irisin. Basal levels of brown/beige and FNDC5 genes correlated positively with the browning response of scWAT to irisin. In addition, irisin significantly inhibited adipogenic differentiation but promoted osteogenic differentiation. We conclude that irisin promotes "browning" of mature white adipocytes by increasing cellular thermogenesis, whereas it inhibits adipogenesis and promotes osteogenesis during lineage-specific differentiation. Our findings provide a rationale for further exploring the therapeutic use of irisin in obesity and exerciseassociated bone formation.
METABOLIC COMPLICATIONS OF OBESITY, including metabolic syndrome and type 2 diabetes mellitus, are worldwide health problems. Obesity results from excessive energy intake compared with energy expenditure, leading to increased adipose tissue mass and ectopic fat accumulation. Brown adipose tissue (BAT), a thermogenic tissue, consumes energy as heat, which is otherwise stored by white adipose tissue (WAT) (30) . The thermogenic capability of BAT is mediated by mitochondria uncoupling protein 1 (UCP1), which uncouples the electron transport chain from energy production, resulting in heat production (39) . Remarkably, the mass of BAT shows an inverse correlation with body mass index (BMI) and adiposity (9, 13) . Thus, by increasing the amount and/or activity of BAT, energy consumption can be increased, and this may serve as a potential therapeutic strategy for obesity and its associated complications.
Irisin, an exercise-induced myokine in mice and humans, promotes "browning" of subcutaneous (sc) white adipocytes by increasing the expression of mitochondrial UCP1 (5) . The precursor of irisin is full-length fibronectin type III domain containing 5 (FNDC5), whose overexpression protects high-fat diet-induced obesity in mice by promoting formation of beige (brite) adipocytes (5) . Recently, we found that in obese mice, recombinant irisin (r-irisin) stimulates browning of white adipocytes via extracellular signal-related kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) signaling, causing weight loss and improved insulin sensitivity (49) . Thus, irisin may be an attractive target for fighting obesity and diabetes (16, 45) .
Although beneficial effects of irisin have been observed in animals, the existence of circulating irisin in humans is controversial due to doubts surrounding the ATA translation start codon in human FDNC5 (35) , the reliability of irisin antibodies (18) , and experimental evidence that commercial irisin ELISA kits are unreliable (2) . However, a recent study has put this controversy to rest by confirming the presence of irisin in human plasma and its elevation after exercise using quantitative mass spectrometry (24) . Nevertheless, the browning effect of irisin in human adipocytes remains controversial (23, 26, 35) . In addition, the ability of exercise per se to stimulate fat browning in humans is still being debated (14, 43) . In this study, we systematically examined the effects of irisin on browning of human primary mature white adipocytes and fresh human scWAT as well as on adipose tissue-derived preadipocytes (stem-like cells) during lineage-specific differentiation. Compared with primary white adipocytes, scWAT fragments represent largely native fat tissue. Our data suggest that irisin increases the expression of beige genes and the UCP1 protein (known as "browning") in both human primary mature white adipocytes and fresh human scWAT. This browning effect is mediated through the p38/ERK MAPK signaling pathways. Treatment of mature white adipocytes with irisin significantly increased cellular thermogenesis. Our data suggest a positive correlation between basal levels of beige gene expression in scWAT and the levels of UCP1 expression of these tissues in response to irisin. Additionally, irisin inhibited adipogenesis during differentiation, supporting its dual roles in converting the mature energy-storing white adipocytes into energy-burning beige adipocytes and suppressing new adipocyte formation. Furthermore, irisin also promoted osteogenic differentiation. To our knowledge, this is the first systematic study of the mechanisms of irisin's effects in human adipose tissue and adipocytes. The data lay the groundwork for further investigating the therapeutic usage of irisin.
METHODS
Production of r-irisin. Production of r-irisin in yeast was performed as described previously (46, 49) .
Harvest of scWAT and perirenal BAT. Human scWAT from breast fat of 28 female donors ages 17-73 yr and perirenal BAT from four donors (3 males and 1 female) were obtained from surgical specimens through the University of Florida, Department of Pathology Grossing Room, according to a protocol approved by the Institutional Review Board. All scWAT donors were females undergoing breast reduction for cosmetic reasons, and all perirenal fat donors were undergoing nephrectomy due to malignancy (renal cell carcinoma). Fat tissues were processed within 6 h after surgery. Adipose tissue (2-5 g/donor) was dissected from surrounding fibrous-vascular tissue and cut into 2-to 3-mm pieces. Adipose tissue fragments were used to obtain preadipocytes from mature adipocytes by ceiling culture or placed directly in flasks for tissue culture. Since a variable amount of adipose tissue was obtained from donors, we triaged our experiments based on sample availability, aiming at five to six donors per group.
Isolation and expansion of human primary preadipocytes. Isolation and expansion of preadipocytes from human scWAT were performed as described with minor modifications (Fig. 1) (19) . Briefly, fresh fat tissue fragments were cultured in T25 flasks filled with basic medium (BM; DMEM-F-12 medium ϩ 10% fetal bovine serum, 100 U/ml penicillin-streptomycin). Fat tissue floated to the top surface of the flask ("ceiling" cultures), and mature adipocytes were attached to the top of the flasks. Preadipocytes dedifferentiated from mature adipocytes were split at ϳ70% confluence at a 1:4 ratio for three to four passages to generate sufficient cells for our experiments, which usually took 2-4 mo.
Differentiation of human preadipocytes into mature adipocytes and osteoblasts. Preadipocytes derived from mature adipocytes are known to possess mesenchymal stem cell (MSC) properties and exhibit multilineage differentiation capacity (20) . Human preadipocytes were cultured in six-well plates until confluent and then induced toward adipogenic differentiation in differentiation medium (DM; BM ϩ 0.5 mmol/l isobutylmethylxanthine, 0.25 mol/l dexamethasone, and 10 mol/l insulin) for 14 days, with fresh medium added every 3rd day. After 14 days, cells were treated with irisin or vehicle for 4 more days to examine whether irisin can induce browning in human mature adipocytes. For osteogenic differentiation, the DM was composed of BM ϩ 0.1 mol/l dexamethasone, 0.2 mmol/l ascorbic acid, and 10 mmol/l ␤-glycerophosphate. Irisin was included in the DM for the entire differentiation period to demonstrate the effect of irisin in osteogenesis. Adipogenic and osteogenic differentiation was confirmed by Oil Red O and alizarin red staining (34) .
Mitochondrial bioenergetics analysis. Preadipocytes were differentiated into mature adipocytes in adipogenic DM for 14 days and then seeded into XF96 Microplates (15,000/well) for 3-4 days in the absence/presence of various irisin concentrations, rosiglitazone (Sigma-Aldrich), or CL316243 (Sigma-Aldrich). Metabolic analyses were performed using a Seahorse Bioscience XF96 Analyzer, which enables real-time simultaneous measurement of oxygen consumption rate (OCR) and extracellular acidification rates (ECAR). Following basal respiration, the mitochondrial effectors (oligomycin, FCCP, and rotenone) were injected sequentially according to our previously established protocols (46) .
Western blotting. Anti-phosphroylated (p)-ERK1/2 (no. 9101), antip-p38 MAPK (no. 9211), and anti-p-STAT3 (no. 9145) antibodies (Cell Signaling Technology), anti-␤-actin (A5316; Sigma-Aldrich), and rabbit anti-UCP1 (AB155117; Abcam) were used for Western blotting. Immunoreactive bands were quantified by densitometry (6, 13) .
RNA isolation and quantitative real-time PCR. Quantitative RT-PCR was performed with ␤-actin RNA as an internal control by the 2 Ϫ⌬⌬CT method (46, 49) . Primer sequences are available upon request.
Immunocytochemistry and immunofluorescence. Adipocytes were fixed with 4% parformaldehyde for 10 min and blocked in the presence of hydrogen peroxide. Cells were incubated with anti-UCP1 antibody (1:500) overnight at 4°C. After washing, the cells were incubated with horseradish peroxidase-conjugated [for immunocytochemistry (ICC)] or Alexa fluor 555-conjugated [for immunofluorescence (IF)] secondary antibody (1-h, 22°C). Nuclei were stained by hematoxylin (ICC) or 4,6-diamidino-2-phenylindole (DAPI; IF).
Adipose tissue culture and browning factors treatment. Fresh human scWAT fragments were cultured overnight in 12-well plates in BM to restore quiescence. For short-term signaling, scWAT fragments were bathed in BM containing either irisin (50 nmol/l), vehicle, or rosiglitazone (1 mol/l) or CL316243 (1 mol/l) for various times with agitation. For browning, scWAT fragments were bathed in BM containing irisin (0.5, 5, or 50 nmol/l) for various times (2, 3, or 4 days) with agitation. Total proteins and RNAs were collected for Western blotting of UCP1 and qRT-PCR gene expression studies.
Statistical analysis. Results are presented as means Ϯ SE of at least three independent experiments. Each experiment was conducted in triplicate. Statistical significance among multiple groups was analyzed using Prism 5 software by one-way ANOVA, followed by post hoc analyses, and between two groups by Student's t-test. P Ͻ 0.05 was considered significant.
RESULTS
Irisin has browning effects on human mature adipocytes derived from scWAT. Human white adipocytes obtained by "ceiling" culture after 3-day culture exhibited mature adipocyte features, including cytoplasmic lipid droplets and dedifferentiated into spindle-shaped MSC-like preadipocytes. The preadipocytes were expanded and redifferentiated into mature adipocytes following 14-day culture in adipogenic DM. Most cells differentiated into mature adipocytes, as evidenced by cytoplasmic lipid droplets (phase) and Oil Red O-stained lipid droplets ( Fig. 1, A 
-C).
We next examined irisin's browning effect on mature primary adipocytes differentiated from preadipocytes of six donors' scWAT (donors 1-6; Fig. 1D ). After adipogenic differentiation, adipocytes treated with irisin (50 nmol/l) for 4 days showed upregulation of browning-related genes (UCP1, PGC1A, and PRDM16) but exhibited individual differences. In contrast, the expression of general adipose genes (PPARG and ADIPOQ) showed no difference between the control and irisin groups (not shown). Next, we analyzed UCP1 protein expression after irisin treatment by ICC ( 
Irisin increased thermogenesis of human mature adipocytes.
To examine effects of irisin on thermogenesis in mature adipocytes isolated from scWAT, we measured mitochondrial respiration. Figure 2 shows that irisin increased OCR (Fig. 2, A and B) and ECAR (Fig. 2, C and D) at effective concentrations as low as 5 nmol/l. Mitochondrial respiration (OCR) of irisin-treated adipocytes was different from that of untreated controls or low dose of irisin-treated cells. In contrast to 0.5 nmol/l irisin, adipocytes treated with 50 nmol/l irisin showed increased basal, uncoupled (oligomycin), and maximal (FCCP) mitochondrial respiration, whereas 5 nmol/l irisin increased basal and uncoupled cellular respiration but not maximal mitochondrial respiration. Adipocytes treated with irisin (5 or 50 nmol/l) also increased glycolysis (ECAR). These data demonstrated that irisin increased cellular thermogenesis by upregulating UCP1, uncoupling oxidative phosphorylation from ATP synthesis, resulting in energy dissipation in the form of heat (15) .
Irisin upregulated UCP1 expression in scWAT by activating ERK/p38 MAPK signaling. The potentially beneficial effects of irisin-mediated browning on human adipocytes led us to probe its potential therapeutic significance. Although assessing irisin's effects directly in human subjects was impractical, fresh human scWAT fragments are suitable for modeling irisin's functions. Our previous murine studies show that irisin activates p38 MAPK and ERK signaling (49) . As shown in Fig. 3 , A and B, phosphorylation of p38 MAPK (p-p38) and ERK (p-ERK) was enhanced by irisin treatment for 60 min. In five donors (donors 7-11), irisin increased p-ERK 2.37 Ϯ 0.41-fold at 60 min and 2.74 Ϯ 0.25-fold at 90 min. p-p38 Levels increased similarly, whereas p-STAT3 was unchanged. To verify the involvement of p38/ERK signaling in UCP1 expression, scWAT fragments were treated with p-p38 (SB-203580) or p-ERK (U-0126) inhibitor for 30 min, followed by irisin. Both abolished irisin-induced upregulation of UCP1 protein (Fig. 3C) , suggesting that activation of p38/ERK MAPK signaling is required for UCP1 expression.
In human adults, adipocytes derived from perirenal adipose tissue were smaller and expressed higher UCP1 compared with scWAT, suggesting that perirenal fat in human adults acts as brown adipose tissue (27, 29, 41) . We also examined whether irisin regulates human perirenal fat, which is classified as BAT. Figure 3D shows that the ERK and p38 were already phosphorylated in untreated perirenal fat and that irisin did not enhance further phosphorylation. Further irisin treatment did not affect UCP1 translation (n ϭ 4; Fig. 3 , E and F) or UCP1 and PRDM16 transcription (n ϭ 3; Fig. 3G ). Thus, our study suggests that human BAT from perirenal fat has high levels of UCP1 protein, and its regulation appears to be irisin independent.
Next, we explored irisin's browning effect in scWAT fragments. Treatment of scWAT with irisin for 4 days increased UCP1 protein (Fig. 4A ) and brown-associated transcripts (UCP1 and PRDM16; Fig. 4B ) in Ͼ75% of scWAT samples. Interestingly, two irisin nonresponders (donors 13 and 17) had relative higher levels of basal UCP1 protein than the irisin responders, suggesting that these fat tissues might be blended Fig. 2 . Effects of irisin on adipocyte thermogenesis. scWAT mature adipocytes were incubated with/without irisin for 4 days. Oligomycin and FCCP were used for determining uncoupled and maximal mitochondrial respiration, respectively. Effects of irisin on cellular oxygen consumption rate (OCR; A and B) and ECAR (extracellular acidification rates; C and D) were measured by XF96 Analyzer. Experimental treatments were performed with 6 technical replicates and 4 biological replicates. *P Ͻ 0.05 and **P Ͻ 0.01 vs. control.
with BAT. Interestingly, irisin treatment of scWAT increased FNDC5 transcript in all donors except for donor 13, suggesting positive autoregulation of irisin, in agreement with previous studies (11, 37) .
To determine the lowest effective dose and shortest duration of irisin treatment, we examined the dose response and time course. As shown in Fig. 4C , irisin increased UCP1 protein (1-and 3-fold at 5 and 50 nmol/l, respectively, P Ͻ 0.01). Surprisingly, as early as day 2 of irisin treatment, UCP1 was increased (P Ͻ 0.01; Fig. 4D ), suggesting that irisin plays an early role in UCP1 expression.
Correlation of basal levels of beige gene expression with irisin-induced browning. Responses to irisin can be fat depot specific (5, 26, 45) . Given these results and our finding that UCP1 protein levels varied among donors after irisin treatment (Fig. 4A) , we hypothesized that the genetic background may affect irisin responsiveness. We measured transcription levels of UCP1 and PRDM16 in eight donors' scWAT after irisin treatment (Fig. 4B) . Responsiveness varied considerably, from no response (donors 13 and 17) to intermediate (donors 12 and 15 for UCP1, 2-to 4-fold increase) to high responsiveness (donors 10, 11, 14, and 16, Ͼ10-fold increase). Next, we determined UCP1, TMEM26, PRDM16, CD137, and FNDC5 expression in scWAT from seven donors prior to irisin treatment (scWAT from donor 10 was insufficient). CD137 and TMEM26 are characteristically expressed by beige cells (45) . scWAT showed highly variable basal levels of all five genes (Fig. 5A) , suggesting that the abundance of beige adipocytes in scWAT differs among individuals and that the relative expression changes of UCP1 and PRDM16 in irisin-treated scWAT were positively correlated with basal levels of UCP1, TMEM26, PRDM16, CD137, and FNDC5 (Fig. 5B ). In contrast, the basal levels of CEBPB and ADIPOQ were similar (not shown). There was no correlation between irisin responsiveness in scWAT and donors' BMI in our limited samples.
Irisin suppressed adipogenic differentiation and promoted osteogenic differentiation. To further explore irisin's contradictory browning effects in human cell models (23, 26, 35) , we examined the longitudinal effects irisin treatment during adipogenic or osteogenic differentiation in six donors (donors 10 Fig. 6A ). After 18 days, mature adipocytes (by morphology and Oil Red O staining) in the irisin-treated group were reduced by 20 -60% compared with controls (Fig. 6B) . Furthermore, irisin decreased CEBPB and ADIPOQ expression (Fig. 6C) . CEBPB and ADIPOQ regulate adipocyte differentiation (25, 44, 48) , and suppression of their expression suggests that irisin exerts an inhibitory effect on adipogenesis. This conclusion was further supported by the fact that irisin decreased expression of browning-related UCP1 and PRDM16 by 10 -65% (Fig. 6C) . Consistent with the transcription results, UCP1 protein expression was reduced when irisin was included throughout adipogenic differentiation (Fig. 6D, bottom ). In contrast, its level increased dramatically when irisin was included only in the last 4 days (Fig. 6D, middle) . Thus, irisin not only induces browning of mature human adipocytes but also inhibits adipogenic differentiation of preadipocytes. Our data suggest that irisin's browning effect is observed only after formation of mature adipocytes, which may explain, at least partly, the conflicting reports of irisin's effects on human adipocytes.
In addition, we examined irisin's effect on osteogenesis in humans since exercise is known to prevent bone loss and reduce fracture risks. Exposure to irisin (50 nmol/l) during differentiation pushed preadipocytes toward osteoblastic differentiation, as evidenced by mineral deposition highlighted by Alizarin Red staining (Fig. 6E) , and enhanced the expression of osteogenic genes RUNX2, OSTERIX, and OSTEOPONTIN in five of six donors (Fig. 6F) . Thus, irisin promotes human osteoblastic differentiation, consistent with recent published murine data (10, 11) .
Comparison of "browning" effect among browning factors. PPARG ligand agonists such as rosiglitazone and ␤ 3 -adrenergic receptor agonists such as CL316243 can induce a beige fat gene program in scWAT (4) . To compare the browning capacity of irisin with traditional browning factors, we tested rosiglitazone and CL-316243. We treated human scWAT fragments from three different donors with 50 nmol/l irisin, 1 mol/l rosiglitazone, or 1 mol/l CL316243 for 3 days. As shown in Fig. 7, A and B , top, both UCP1 protein and gene expression were increased significantly after all three treatments, and irisin seemed more potent on a molar basis than rosiglitazone and CL-316243. In addition, the cotranscriptional regulator PGC1A induces mitochondrial biogenesis by activating nuclear respiratory factors (NRF1 and -2) (32). We found that not only rosiglitazone and CL-316243 but also irisin stimulated PGC1A and NRF1 expression (Fig. 7B, middle and bottom) , suggesting that irisin also has a positive effect on mitochondrial biogenesis and cellular metabolism.
Next, we compared the thermogenic effect of rosiglitazone, CL-316243, and irisin on human mature adipocytes isolated from scWAT. Figure 7 , C-E, shows that both OCR and ECAR at basal and peak levels increased significantly following treatment with irisin, rosiglitazone, or CL-316243. The browning effect of irisin is comparable with rosiglitazone and CL-316243.
DISCUSSION
Animal studies suggest that irisin is an attractive therapeutic target for obesity and metabolic disorders (7, 11, 21, 22, 33, 49) . However, its effects in humans are controversial. The present study addressed this gap in our understanding of irisin's action on human fat by using human primary adipocytes and fresh scWAT. We found that 1) in white adipocytes, irisin upregulated expression of browning-associated genes and UCP1 protein and increased thermogenesis of ma- ture adipocytes significantly; 2) this action was mediated by the p38/ERK MAPK pathways since the UCP1 expression was abolished by pathway-specific inhibitors; 3) the abundance of beige adipocytes in scWATs correlated positively with responsiveness to irisin treatment; 4) irisin positively autoregulates FDNC5 expression in adipose tissue; and 5) irisin inhibits adipogenesis, reducing the formation of new adipocytes, and promotes osteoblastic differentiation. These results suggest that irisin may have promising aspects for treatment/prevention of human obesity and osteoporosis.
The browning effects of irisin in humans are controversial. Raschke et al. (35) incubated primary human subcutaneous preadipocytes with FNDC5 and irisin for 18 days and found no browning effect. In contrast, Lee et al. (26) showed that 6-day FNDC5 treatment of human mature adipocytes strongly induced the expression of brown and beige genes. Furthermore, Huh et al. (23) found that browning genes (UCP1, PRDM16, and CIDEA) were induced in human mature adipocytes 8 days after irisin stimulation. These conflicting observations suggest that irisin's browning effects depend on the maturity of adi- Fig. 6 . Irisin inhibits adipogenic and promotes osteogenic differentiation. A: preadipocyte differentiation to adipocytes or osteoblasts in the presence of irisin (50 nmol/l) for 18 or 21 days, respectively. B: mature adipocytes (arrows) were confirmed by Oil Red O staining (left) and mature adipocytes in irisin-treated cells were calculated as %control (right). C: expression of adipogenic genes (CEBPB and ADIPOQ) and browning genes (UCP1 and PRDM16) was determined by quantitative RT-PCR (qRT-PCR; *P Ͻ 0.05 and **P Ͻ 0.01 vs. control). D: cells were stained with anti-UCP1 antibodies and detected by IF. Green, UCP1 protein; blue, DAPI-stained nuclei. Micrographs are merged photos of UCP1, DAPI, and phase images. E: differentiated osteoblasts were confirmed by alizarin staining. F: the expression of OPN, OSTERIX, and RUNX2 genes was determined by qRT-PCR (*P Ͻ 0.05 and **P Ͻ 0.01 vs. control). AD, adipocyte. Fig. 7 . Comparison of the browning effect by 3 browning reagents. A and B: human scWAT fragments from breasts of donors 26 -28 were treated with 50 nmol/l irisin, 1 mol/l rosiglitazone, or 1 mol/l CL-316243 for 3 days. UCP1 protein level was measured by Western blotting. Bar graphs represent UCP1 expression relative to actin (A). UCP, PGC1A, and NRF1 mRNA expression was measured by qRT-PCR (B). C-E: mature human adipocytes were treated with 50 nmol/l irisin, 100 nmol/l rosiglitazone, or 100 nmol/l CL-316243 for 3 days. Then, OCR (C and D) and ECAR (E) were measured by Seahorse XF96 Analyzer. Experimental treatments were performed with 6 technical replicates and 4 biological replicates. *P Ͻ 0.05 and **P Ͻ 0.01 vs. control.
pocytes. To resolve this, we used two human models, cultured primary mature adipocytes and stem-like preadipocytes, to help reconcile the discrepancy.
Irisin promoted expression of UCP1 and other brown-related genes in mature adipocytes (Fig. 1) , consistent with the findings by Lee et al. (23) and Huh et al. (26) . However, opposite effects were obtained when human preadipocytes were induced toward adipogenic differentiation in the presence of irisin during this process (Fig. 6) . The marked reduction of mature adipocytes and decreased expression of adipogenic differentiation genes (CEBPB and ADIPOQ) and BAT-related genes (UCP1 and PRDM16) suggest that irisin exerts inhibitory effects on adipogenesis, and no browning effect was observed if irisin was added during stem cell adipogenic differentiation, which is consistent with the results of Raschke et al. (35) . Our studies thus suggest that the effects of irisin in humans are likely differentiation stage dependent. Irisin effectively reprogrammed mature adipocytes into brown-like adipocytes by increasing UCP1 expression (Figs. 1 and 4) , and this browning action of irisin is supported further by increased mitochondrial basal, uncoupled, and maximal respiration or thermogenesis following irisin stimulation (Fig. 2) . Therefore, our results provide further support for irisin's browning action on mature white adipocytes and scWAT.
Our findings highlight that irisin not only increases cellular thermogenesis by browning scWAT but also reduces fat storage by suppressing formation of new adipocytes. Recently, Xiong et al. (47) demonstrated that irisin increased hormonesensitive lipase (HSL) expression and reduced perilipin, increasing lipolysis via the cAMP-PKA-HSL/perilipin pathway. This finding may be another possible mechanism by which irisin counters obesity.
The present data contribute to our understanding the role of irisin in human adipose tissue. Adipose tissue consists primarily of mature adipocytes, along with scant stem cells, fibrovascular components, and other cell types, and it has varied roles in regulating metabolism (1) . In vitro adipocyte culture is used widely to investigate adipose tissue biology (6) , and previous studies of irisin's browning effects have employed this system (23, 26, 35) . However, derivation of human primary mature adipocytes involves in vitro dedifferentiation and redifferentiation. The epigenetic changes associated with these processes, the loss of other types of cells, and the lack of three-dimensional structure are limitations of this approach (8, 40) . To more accurately evaluate the in vivo therapeutic roles of irisin, we developed a human adipose tissue culture system. As shown in Fig. 4A , irisin increased the UCP1 protein in scWAT fragments from different donors to various degrees, and this action was mediated by activating the ERK and p38 MAPK signaling pathways. Inhibition of either pathway with specific inhibitors abolished irisin-stimulated UCP1 protein to baseline levels (Fig. 4C) , consistent with our murine data (49) . Further studies are needed to understand how the activation of these pathways leads to overexpression of UCP1. Nonetheless, our results provide further experimental evidence in support of irisin's browning effect in humans, laying the groundwork for future investigation of the potential therapeutic use of irisin.
Adipose tissues are widespread, and adipocytes at different anatomic locations show different characteristics (3). It is reported that classical brown adipocytes are found in the major dedicated BAT depots of rodents, such as in the interscapular, perirenal, and periaortic regions (38) . In human adults, active BAT depots are found in the cervical, supraclavicular, axillary, paravertebral, and perirenal regions (38, 41) . Lee et al. (26) showed that FNDC5 (irisin precursor) enhances a BAT-like thermogenic program in neck adipocytes and to a lesser extent subcutaneous adipocytes, but this shows an unclear role in omental visceral adipocytes, suggesting that the response to irisin may be fat depot specific. In our studies, breast scWAT samples showed variable responses of UCP1 expression in response to irisin (Fig. 4) , whereas irisin responsiveness, although limited in seven to eight donors, appears to positively correlate with the basal levels of brown and beige adipocyte genes (Fig. 5A) , suggesting that the abundance of beige adipocytes in scWAT differs among donors, even at the same location. The correlation of irisin-stimulated UCP1 expression with the basal levels of beige-specific genes suggests that beige adipocytes within scWAT are preferentially sensitive to the browning effect of irisin. However, irisin-treated BAT from perirenal fat showed no further activation of p38/ERK MAPK signaling or expression of UCP1/PRDM16 (Fig. 3, D-G) . The concept of different types of fat cells, in particular different types of thermogenic fat cells, in humans is still very new, and more studies are needed. Our results offer a potential means to assess irisin's therapeutic effects in humans.
In this study, we found that scWAT from breast fat of different donors exhibited individual differences in the extent of irisin-induced UCP1 expression (Fig. 4) . To further investigate the reason, the expression of beige genes in different donors was measured. We found that the abundance of beige genes in breast fat differs among individuals. The relative expression changes of UCP1 in irisin-treated breast fat positively correlated with basal levels of UCP1, TMEM26, PRDM16, CD137, and FNDC5 (Fig. 5) . In addition, human genetic mutations/variations such as polymorphisms of UCP1 (Ϫ3826A/G) and the ␤ 3 -adrendergic receptor (ADRB3) (64 Trp/Arg) (28, 42) affect beige/brown fat development and energy metabolism, which may be an important reason for the variable responsibility to irisin.
To this end, we compared the browning effect of irisin with that of two well-known agonists, rosiglitazone and CL316243. As shown in Fig. 7, A and B, treatment of human scWAT fragments with 50 nmol/l irisin, 1 mol/l rosiglitazone, or 1 mol/l CL-316243 robustly induced mRNA expression and protein level of UCP1 as well as the mitochondrial biogenesis genes PGC1A and NRF1. Moreover, treatment of human mature adipocytes with 50 nmol/l irisin, 100 nmol/l rosiglitazone, or 100 nmol/l CL-316243 increased both OCR and ECAR. Although the concentration of rosiglitazone and CL-316243 used was higher than irisin, the browning and thermogenesis effects of irisin were similar to that of the other browning factors. Currently, there is no consensus regarding the physiological range of circulating irisin during rest and exercise (2, 17) . Estimates vary from 5 to 1,200 ng/ml in different settings using commercial ELISA kits (12, 31) . A recent study examined these ELISA kits and discovered that they lack specificity, casting doubt on the previous measurements of circulating irisin levels (2) . In most experiments here, we chose an irisin concentration of 50 nmol/l and at this dose we found a significant browning effect of scWAT at tissue and adipocyte levels. Recently, Jedrychowski et al. (24) confirmed the presence of circulating irisin in human plasma at ϳ3.6 -4.3 ng/ml.
To search for the lowest effective dose of irisin for browning, we examined irisin's effect on mitochondrial respiration and UCP1 expression at 0.5 and 5 nmol/l. We found that at 5 nmol/l, r-irisin from yeast had a browning effect, as evidenced by increased cellular metabolism (Fig. 2 ) and UCP1 expression (Fig. 4C) . Although further studies are required to define the exact physiological range of circulating and local irisin, 5 nmol/l used in our study could be considered to be within the physiological range of most circulating hormones and myokines (24) , especially considering the low biological activity of recombinant irisin (46) . Interestingly, since WAT produces irisin (36) , circulating irisin levels may be lower than the local irisin concentration due to paracrine and autocrine regulation.
Because of the limited clinical data available, we could not analyze the correlation of irisin sensitivity with sex, difference percentage of body fat, systolic and diastolic blood pressure, fasting glucose, triglycerides, and HOMA-IR. However, with our limited data, we failed to find any correlation between donors' BMI and the responsiveness to irisin in scWAT.
In conclusion, we found that irisin has significant browning effects on human mature white adipocytes and increases adipocyte thermogenesis. The browning action is mediated via p38/ERK signaling, and irisin responsiveness likely correlates with the numbers of beige adipocytes within scWAT. In contrast, irisin exerts an inhibitory effect on adipocyte formation and promotes osteogenesis during preadipocyte differentiation. Our findings provide experimental evidence supporting the possible therapeutic use of irisin in treating human obesity and osteoporosis.
